As a breakthrough in oncology, ICI has brought about an unimaginable improvement in the landscape of advanced-stage cancer treatment, such as lung cancer; thus, these treatments (anti-PD-1/PD-L1 immunotherapy) are now widely used in clinical practice. Here, PDCD1 is linked to lung carcinoma.